Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 9/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 8/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045458 | 0.95 | EGFR (0.42) | BTKEGFR | |
| SCHEMBL20045453 | 0.95 | KRAS (0.39) | KDM5ABTKLCKSRCEGFR | |
| SCHEMBL20132862 | 0.93 | KDM4E (0.38) | BTKLCKSRCEGFRKRAS | |
| SCHEMBL20045462 | 0.86 | KRAS (0.38) | KDM5ABTKLCKSRCEGFR | |
| SCHEMBL20045428 | 0.85 | KRAS (0.39) | BTKLCKSRCEGFRKRAS | |
| SCHEMBL20132849 | 0.82 | ACHE (0.42) | KDM5ABTKEGFRKRASFGFR1 | |
| SCHEMBL20132942 | 0.81 | KRAS (0.38) | BTKLCKSRCEGFRKRAS | |
| SCHEMBL20045452 | 0.80 | KDM4E (0.36) | BTKLCKSRCEGFRKRAS | |
| SCHEMBL20045950 | 0.80 | KDM4E (0.36) | BTKLCKSRCEGFRKRAS | |
| SCHEMBL20046515 | 0.80 | KRAS (0.37) | BTKLCKSRCEGFRKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | KDM5A 4095/4885BTK 758/4885LCK 2643/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KDM5A 4040/4885BTK 559/4885LCK 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.